Literature DB >> 10471356

The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions.

A G Brittsan1, E Kiss, I Edes, I L Grupp, G Grupp, E G Kranias.   

Abstract

The aim of the present study was to determine the effects of beta -adrenergic stimulation in wild-type and phospholamban-deficient mouse hearts with altered thyroid conditions. Hypothyroidism was associated with significant decreases in heart/body weight ratio in wild-type and phospholamban-deficient mice, whereas hyperthyroidism was associated with significant increases in heart/body weight ratio in both groups. Hypothyroid hearts of wild-type and phospholamban-deficient mice exhibited similar increases in beta -myosin heavy chain protein levels and decreases in alpha -myosin heavy chain protein levels. In hyperthyroidism, there were increases in the alpha -myosin heavy chain protein levels and these were similar in wild-type and phospholamban-deficient hearts. There were no detectable levels of beta -myosin heavy chain protein in the hyperthyroid hearts. The relative tissue level of phospholamban in wild-type hearts was increased (133%, P<0.01) in hypothyroidism, and decreased (69%, P<0.01) in hyperthyroidism, when compared to euthyroid controls (100%). Similar increases and decreases in SR Ca(2+)-ATPase protein levels were observed between phospholamban-deficient and wild-type hearts in hyperthyroidism and hypothyroidism, respectively. The basal contractile state of wild-type and phospholamban-deficient hearts was significantly depressed in hypothyroidism. On the other hand, the basal contractile state of wild-type and phospholamban-deficient hearts was significantly increased in hyperthyroidism. During beta -agonist stimulation of wild-type hearts, the responses in the rates of contraction and relaxation were highest in the hypothyroid group, followed by the euthyroid, and lastly by the hyperthyroid groups. There was a close linear correlation between the magnitude of the contractile parameter responses and the phospholamban/SERCA2 ratios in these hearts. However, the phospholamban-deficient hypothyroid, euthyroid, and hyperthyroid hearts did not exhibit any responses to isoproterenol, indicating that the alterations in the thyroid states of these hearts do not influence the effects of isoproterenol on cardiac function. These findings suggest that phospholamban is an important regulator of the heart's responses to beta -adrenergic stimulation under various thyroid states. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471356     DOI: 10.1006/jmcc.1999.1010

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  5 in total

Review 1.  Determinants of frequency-dependent contraction and relaxation of mammalian myocardium.

Authors:  Paul M L Janssen; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2007-08-28       Impact factor: 5.000

2.  Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats.

Authors:  Roland Vetter; Uwe Rehfeld; Christoph Reissfelder; Henry Fechner; Enn Seppet; Reinhold Kreutz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

Review 3.  Altered cardiac calcium handling in diabetes.

Authors:  Darrell D Belke; Wolfgang H Dillmann
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

4.  A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Authors:  Kobra Haghighi; Guoli Chen; Yoji Sato; Guo-Chang Fan; Suiwen He; Fotis Kolokathis; Luke Pater; Ioannis Paraskevaidis; W Keith Jones; Gerald W Dorn; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

5.  High-Density Genotypes of Inbred Mouse Strains: Improved Power and Precision of Association Mapping.

Authors:  Christoph D Rau; Brian Parks; Yibin Wang; Eleazar Eskin; Petr Simecek; Gary A Churchill; Aldons J Lusis
Journal:  G3 (Bethesda)       Date:  2015-07-28       Impact factor: 3.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.